BlossomHill Therapeutics, Inc. BLSM
14.24 USD -0.22 (-1.52%)
At closeNov 10, 2026, 4:00 PM EST
14.24 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
12.97 Day range 14.56
11.02 52-week range 27.99
- YTD
- -11.00%
- 1 year
- -11.00%
News
benzinga.com BlossomHill Therapeutics Announces Alignment With FDA On 50mg Twice Daily As Recommended Phase 2 Dose For BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027
globenewswire.com BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC Alignment with the US Food and Drug Administration on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational…
globenewswire.com BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and…
globenewswire.com BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and…
seekingalpha.com BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price BlossomHill Therapeutics achieved major de-risking milestones within 80 days post-IPO, including Fast Track and a key companion diagnostic partnership. I see the C797S lung cancer indication as a…
benzinga.com BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines…
globenewswire.com BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and…
defenseworld.net BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell? BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report)'s share price traded down 4.9% on Wednesday. The stock traded as low as $20.33 and last traded at $20.33. Approximately 22,349 shares…
defenseworld.net BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report) shares gapped up before the market opened on Tuesday. The stock had previously closed at $19.75, but opened at $21.17. BlossomHill…
benzinga.com BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027 Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND…
globenewswire.com BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND…
benzinga.com Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40 Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.- benzinga.com Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40 Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.
benzinga.com Earnings Scheduled For September 18, 2026 Companies Reporting Before The Bell • BlossomHill Therapeutics (NASDAQ:BLSM) is expected to report earnings for its second quarter. Companies Reporting After The Bell This article was generated by…
benzinga.com BlossomHill Therapeutics Q2 EPS $(8.75) BlossomHill Therapeutics (NASDAQ:BLSM) reported quarterly losses of $(8.75) per share. This is a 58.8 percent decrease over losses of $(5.51) per share from the same period last year.
globenewswire.com BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR…
benzinga.com BlossomHill Therapeutics Announces Updated Data From Ongoing Phase 1/2 SOLARA Trial Of BH-30643 In NSCLC Patients With Secondary EGFR Resistance Mutations Such As EGFR C797S 45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat…
globenewswire.com BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer 45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat…
defenseworld.net BlossomHill Therapeutics, Inc.’s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM) BlossomHill Therapeutics' (NASDAQ: BLSM - Get Free Report) quiet period will end on Wednesday, September 16th. BlossomHill Therapeutics had issued 9,375,000 shares in its public offering on August…
globenewswire.com BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and…- benzinga.com LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32 LifeSci Capital initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $32.
- benzinga.com Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36 Leerink Partners initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $36.
- benzinga.com JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28 JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Overweight rating and announces Price Target of $28.
- benzinga.com Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30 Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $30.
benzinga.com This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
globenewswire.com BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S BH-30643 was recently granted Fast…
benzinga.com HC Wainwright & Co. Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $35 HC Wainwright & Co. analyst Robert Burns initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $35.- benzinga.com Blossomhill Says FDA Grants Fast Track Designation To BH-30643 For Treatment Of Adult Patients With Advanced Or Metastatic EGFR C797S-Positive NSCLC After Prior Treatment With Third-Gen EGFR Tyrosine Kinase Inhibitor BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines…
globenewswire.com BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and…
defenseworld.net BlossomHill Therapeutics (NASDAQ:BLSM) Director Bihua Chen Purchases 312,500 Shares of Stock BlossomHill Therapeutics, Inc. (NASDAQ: BLSM - Get Free Report) Director Bihua Chen acquired 312,500 shares of the business's stock in a transaction dated Monday, August 10th. The shares were bought…
globenewswire.com BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based…
seekingalpha.com BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise BlossomHill Therapeutics is seeking a $125 million IPO to advance its oncology pipeline, focused on EGFR-mutant NSCLC. I see early clinical data for BH-30643 as promising, supporting a potential…